Literature DB >> 3839010

Curability of Burkitt's lymphoma with high-dose cyclophosphamide-high-dose methotrexate therapy and intrathecal chemoprophylaxis.

M P Sullivan, I Ramirez.   

Abstract

Twenty-four children with Burkitt's lymphoma were treated beginning May 1976 with a regimen alternating high doses of cyclophosphamide and methotrexate in induction and consolidation; only high doses of methotrexate were used in the maintenance phase. Throughout therapy, which was planned for 54 weeks, intrathecal chemoprophylaxis using methotrexate, cytosine arabinoside, and hydrocortisone was coordinated with the high-dose methotrexate infusion therapy to provide CNS chemoprophylaxis that maintained therapeutic methotrexate spinal fluid levels (greater than 10(-6) mol/L) for approximately 60 hours. Twenty-two (92%) of the 24 children attained complete remission; two (8.3%) patients attained only partial remission, failing therapy. Two children died of infection while in complete remission; two children relapsed on therapy. Actual survival is 75%; the median follow-up time is 38+ months (range, 1 1/2+ to 84+ months). Relapses correlated with Murphy disease stage as follows: stage I--0/3, stage II--2/7, stage III--2/10, and stage IV--0/2. Serious side effects and toxicities of chemotherapy occurred in ten patients (metabolic disturbances after rapid tumor lysis, two; infectious and/or febrile episodes following cyclophosphamide therapy, three; methotrexate side effects, four; and complications of intrathecal therapy, one). Results of this therapy are similar to those of the best regimens that have been reported. Treatment has been adapted for use in Burkitt's lymphoma by the Pediatric Oncology Group; the responsiveness of other B cell lymphomas of childhood to this treatment is also being determined.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3839010     DOI: 10.1200/JCO.1985.3.5.627

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  4 in total

Review 1.  Advances in management of non-Hodgkin lymphoma.

Authors:  T S Vats
Journal:  Indian J Pediatr       Date:  1987 Nov-Dec       Impact factor: 1.967

Review 2.  Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.

Authors:  Melissa M Hudson; Joseph P Neglia; William G Woods; John T Sandlund; Ching-Hon Pui; Larry E Kun; Leslie L Robison; Daniel M Green
Journal:  Pediatr Blood Cancer       Date:  2011-10-28       Impact factor: 3.167

3.  Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.

Authors:  Joseph A Sparano; Jeannette Y Lee; Lawrence D Kaplan; Alexandra M Levine; Juan Carlos Ramos; Richard F Ambinder; William Wachsman; David Aboulafia; Ariela Noy; David H Henry; Jamie Von Roenn; Bruce J Dezube; Scot C Remick; Manisha H Shah; Lawrence Leichman; Lee Ratner; Ethel Cesarman; Amy Chadburn; Ronald Mitsuyasu
Journal:  Blood       Date:  2009-12-18       Impact factor: 22.113

4.  Intensive chemotherapy for non-localised Burkitt's lymphoma.

Authors:  A Al-Attar; J Pritchard; T Al-Saleem; M Al-Naimi; N Alash; A Attra
Journal:  Arch Dis Child       Date:  1986-10       Impact factor: 3.791

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.